RETOUR

ABOUT LFB BIOPHARMACEUTICALS

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard

Adverse events should also be reported to Medical Information, Pharmalex, Tel: 01628 531171 medinfo.uk@pharmalex.com

Job Code: 22/11/082 – Date of preparation: January 2023

About LFB BIOPHARMACEUTICALS

LFB BIOPHARMACEUTICALS Ltd. was created in 2015 to support the availability of LFB’s biopharmaceutical products for serious and rare diseases to patients in the United Kingdom. The role of LFB BIOPHARMACEUTICALS is to facilitate the compliant provision of medicines to health care institutions and to support the medical needs of patients and healthcare professionals.

The therapeutic areas in which we currently provide medical and scientific support include:

  • Immunology
  • Haemostasis
  • Intensive care

LFB BIOPHARMACEUTICALS is also responsible for communication to healthcare professionals for LFB products in the UK.

Committed to healthcare professionals, their patients and their families

LFB BIOPHARMACEUTICALS has dedicated itself to providing care and support to patients with rare diseases. In the UK this is reflected in in the therapy areas in which we operate, including haemophilia and von Willebrand’s disease. These patient organisations provide assistance for patients with rare bleeding disorders and their families.

The patient organisations we support include:

  • Haemnet
  • Immune Deficiency Patient Group Wales
  • Immunodeficiency UK
  • Immunology and Allergy Nurse Group
  • The Haemophilia Society
  • Thrombosis UK
  • University Hospitals Birmingham Charity

A company committed to patients’ lives

LFB is one of Europe’s leading biopharmaceutical companies. Originally formed in 1994, today, we employ over 2,500 people, both in France and worldwide. We supply 15 biopharmaceuticals, including plasma derived and recombinant medicinal products, to approximately 30 countries treating hundreds of thousands of patients.

Currently, LFB has four bioproduction sites worldwide, three of which are in France, with a new industrial site in Arras under development. Completion of this site will triple production capacity. Allied to this industrial transformation, we are also focused on cultural transformation to ensure our evolving workforce and working practices are aligned with our values.

  • Act with exemplarity,
  • Develop team spirit,
  • Dare to take initiative,
  • Cultivate excellence,
  • Succeed with integrity.

A full list of payments from 2020-2023 to patient organisations is available below: 

A FULL LIST OF PAYMENTS FROM 2020-2023 TO HEALTHCARE PROFESSIONALS IS AVAILABLE BELOW:

Contributions to UK Members of the Public, including Patients and Journalists 2023:

Also discover